Argenx — Sponsor Intelligence | 33 EU Trials

Filter these 33 trials by condition, phase, country and more.

Open in Search →

33 Registered trials

13 Recruiting

20 Completed trials

26 Countries active

18 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 14 Phase II/III: 6 Phase II: 9 Phase I/II: 1 Phase I: 1 Phase I (Other): 2

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

20 of 20 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Myasthenia gravis 6 Endocrine ophthalmopathy 2 Multifocal motor neuropathy 2 Ocular myasthenia 1 Amyotrophic lateral sclerosis 1 Dermatomyositis 1 Delayed graft function 1 Congenital myasthenic syndrome 1 Idiopathic inflammatory myopathy 1

Top IMPs

EFGARTIGIMOD ALFA 22 EMPASIPRUBART 7 ADIMANEBART 1

All trials

33 total

MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth… Recruiting

2025-522492-28-00 Phase II 7 countries EFGARTIGIMOD ALFA; EMPASIPRUBART
A study to assess the efficacy and safety of empasiprubart in adults with CIDP Recruiting

2025-520805-10-00 Phase III 15 countries EMPASIPRUBART
A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting

2024-520097-36-00 Phase III 19 countries EMPASIPRUBART
A study to assess the effect and safety of efgartigimod IV in participants from 12 years to less than 18 years of age with chronic Immune Th… Recruiting

2025-521055-23-00 Phase II/III 8 countries EFGARTIGIMOD ALFA
A study to assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia Recruiting

2024-515451-38-00 Phase III 14 countries EFGARTIGIMOD ALFA
A Phase 1b study to investigate safety and tolerability of ARGX-119 in adult participants with DOK7 Congenital Myasthenic Syndrome (CMS) Recruiting

2023-509872-41-00 Phase I/II 4 countries
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Subcutaneously in Children With Generalized Myasthenia Gravis (AD… Recruiting

2023-507379-23-00 Phase II/III 9 countries EFGARTIGIMOD ALFA
A study to assess the efficacy and safety of efgartigimod PH20 SC in adults with systemic sclerosis (eSScape) Recruiting

2024-514539-67-00 Phase II 16 countries EFGARTIGIMOD ALFA
A Phase 2 study to Evaluate the Safety, Tolerability and Efficacy of Efgartigimod PH20 SC given by prefilled syringe in Kidney Transplant Re… Recruiting

2023-508180-72-00 Phase II 6 countries EFGARTIGIMOD ALFA
A study of efgartigimod PH20 SC in children between 2 and less than 18 years of age with generalized myasthenia gravis Recruiting

2023-506159-12-00 Phase II/III 8 countries EFGARTIGIMOD ALFA
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting

2022-502851-79-00 Phase III 19 countries EFGARTIGIMOD ALFA
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasth… Recruiting

2024-513854-31-00 Phase II/III 7 countries EFGARTIGIMOD ALFA
A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with chronic inflammatory demyel… Recruiting

2023-507885-21-00 Phase II 11 countries EFGARTIGIMOD ALFA
A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor Neuropathy Ended

2024-516473-72-00 Phase III 19 countries EMPASIPRUBART
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended

2024-516609-22-00 Phase III 18 countries EFGARTIGIMOD ALFA
A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravis Ended

2024-514133-38-00 Phase III 15 countries EFGARTIGIMOD ALFA
A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative… Ended

2024-511796-15-00 Phase III 15 countries EFGARTIGIMOD ALFA
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (Varvara) Ended

2022-503091-89-00 Phase II 7 countries EMPASIPRUBART
A clinical trial to investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of A… Ended

2023-507052-69-00 Phase II 8 countries EMPASIPRUBART
A study to investigate the efficacy and safety of efgartigimod PH20 SC in adult participants with active idiopathic inflammatory myopathy Ended

2024-512785-33-00 Phase II/III 19 countries EFGARTIGIMOD ALFA
Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopeni… Ended

2024-513147-90-00 Phase III 6 countries EFGARTIGIMOD ALFA
A study to assess the safety of ARGX-121 in Healthy Adult Participants Ended

2025-521524-30-00 Phase I 1 country
A study to evaluate safety and efficacy of Empasiprubart in adults with Dermatomyositis Ended

2023-508337-14-00 Phase II 4 countries EMPASIPRUBART
A study to assess the effects of efgartigimod on emasiprubart in healthy adult participants Ended

2024-517511-70-00 Phase I (Other) 1 country

Showing 1–24 of 33 trials

← All sponsors A–Z